Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 06, 2026
TickeronGET DAILY SIGNALS
Why Is Option Care Health (OPCH) Stock Up +32.91% Today?

Why Is Option Care Health (OPCH) Stock Up +32.91% Today?

Key Takeaways

  • OPCH shares jumped roughly 32.9% to about $31.06, from a prior close of $23.37.
  • The primary catalyst is a definitive agreement for private equity firm Clayton, Dubilier & Rice (CD&R) and McKesson to acquire Option Care Health for $32.05 per share, or roughly $5.8 billion in enterprise value.
  • The agreed price represents a premium of approximately 37% to the October 5 closing price.
  • CD&R will hold about 51% and McKesson about 49%, with a framework for McKesson to later acquire CD&R's stake.
  • Secondary support came from analyst commentary, including Truist reiterating a Buy rating.
  • Traders are now watching the gap between the current price and the $32.05 deal price, plus regulatory and shareholder approvals ahead of an expected first-half 2027 close.

Opening Summary

Option Care Health, Inc. (OPCH), the largest independent provider of home and alternate-site infusion services in the United States, staged a powerful rally on Tuesday. Shares climbed about 32.9% to trade near $31.06, up from a prior closing price of $23.37. The move followed the announcement that CD&R and McKesson (MCK) had signed a definitive agreement to acquire the company, taking it private at $32.05 per share.

The Definitive Acquisition Agreement

The decisive driver behind the surge was a confirmed buyout. Under the terms, CD&R and McKesson will acquire OPCH for $32.05 per share in cash, valuing the company at approximately $5.8 billion including debt. The agreed price reflects a premium of roughly 37% over the October 5 closing price, explaining the sharp repricing of the stock toward the deal value.

At closing, CD&R is expected to hold a majority interest of about 51%, while McKesson will invest roughly $1.4 billion for a minority stake of about 49%. The agreement also establishes a framework for McKesson to acquire CD&R's interest in the future, subject to specified conditions and regulatory approvals. Option Care Health is expected to remain a separate company led by its existing management team.

Strategic Rationale and Sector Context

The transaction underscores growing strategic interest in home and community-based infusion care, a segment benefiting from an aging population and the shift of care toward lower-cost, patient-preferred settings. McKesson framed the investment as aligned with its long-term strategy to expand access and affordability for specialty and complex therapies across the care continuum. The deal is also the latest in a series of private equity acquisitions targeting home health services providers, reinforcing investor appetite for the sector.

Analyst Reaction

Analyst commentary provided secondary support. Truist Securities reiterated a Buy rating, citing Option Care Health's strong payer relationships, including in-network status with the top ten plans and coverage of roughly 96% of insured lives, as well as the company's free-cash-flow generation. The firm pointed to the platform's strategic positioning amid durable demand drivers in infusion and alternate-site care.

Market Context and Trading Activity

Trading volume was heavily elevated relative to typical sessions as investors repriced OPCH toward the announced deal value. The rally was company-specific rather than a broad market event, with the stock's move far outpacing the major indices. Notably, the shares settled somewhat below the $32.05 offer price, reflecting a deal spread that accounts for the time to closing and the customary execution risks associated with a transaction expected to complete in the first half of 2027.

What Comes Next for OPCH

The path ahead for OPCH will be shaped primarily by the mechanics of completing the transaction. Shareholders must approve the deal, and the closing remains subject to required regulatory approvals and other customary conditions. Given the expected first-half 2027 completion timeline, the stock is likely to track developments around regulatory review and any potential changes to deal terms. A termination of the agreement would expose shares to downside toward pre-announcement levels. The company's previously reported second-quarter results beat consensus estimates, with adjusted EPS of $0.45 versus expectations of $0.43 and revenue of $1.44 billion, providing fundamental context amid the acquisition-driven repricing.

Trending AI Robots

For traders seeking a systematic approach to markets like this, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches suited to their objectives. Visit the Trending AI Robots page to discover which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OPCH

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


OPCH sees MACD Histogram crosses below signal line

OPCH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 38 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for OPCH moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 15 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 73 cases where OPCH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPCH as a result. In 61 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

OPCH broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 50-day moving average for OPCH moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +0.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 175 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

The Aroon Indicator entered an Uptrend today. In 156 of 221 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OPCH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.763) is normal, around the industry mean (204.532). P/E Ratio (23.797) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).

The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 59%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 48
Price Growth Rating: 58
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of home and alternate site infusion services.

Industry HospitalNursingManagement

Industry
N/A
Address
3000 Lakeside Drive
Phone
+1 312 940-2443
Employees
8266
Web
https://www.optioncarehealth.com
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.